Should I Buy AstraZeneca Plc?

Harvey Jones asks whether AstraZeneca plc (LON: AZN) is still bad medicine.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m shopping for shares again, should I pop AstraZeneca (LSE: AZN) (NYSE: AZN.US) into my basket?

The drugs don’t work

If you’re looking for a solid, defensive FTSE 100 stalwart, then look away now, because AstraZeneca isn’t it. The pharmaceutical giant has spent years trying to remedy expiring patents and a failing drugs pipeline, with mixed results. Broker forecasts are dismal, ranging from ‘underperform’, to ‘neutral’, to ‘hold’. Should I buck the trend and buy it?

Last time I looked at AstraZeneca, in October, I wrote that its share price had gone nowhere, slowly, for years. Patents were running out, its pipeline of replacement drugs was blocked, and management had resorted to sacking nearly 10% of its staff to shed weight. Since then, the share price has recovered a modest 9% to £33.07, although the FTSE 100 rose more than 13% over the same period. The longer-term share price story is uglier, with just 1% growth in three years against 22% for the FTSE 100 and an impressive 51% for arch rival GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Profits plunge

AstraZeneca’s Q1 results piled on the misery, with a 13% fall in group revenue to £6.38bn, as it lost exclusivity for key drugs, and a 36% drop in pre-tax profits to $1.3bn. It wasn’t all bad news. Like many FTSE 100 companies, AstraZeneca is having more joy further afield, with sales rising 9% in emerging markets. It boasts 84 products in its drugs pipeline, and recently struck a deal with Amgen, the world’s largest biotechnology company, to develop five biotech drugs. AstraZeneca publishes its Q2 results on Thursday, when the market will be looking to see when its drugs pipeline will wash into the market.

I did like one thing about AstraZeneca: its yield. That was 6.1% in October and remains a peppy 5.6%, covered 2.3 times, easily beating GlaxoSmithKline’s 4.4% yield. There was something else to like, AstraZeneca’s lowly valuation of just 7.8 times earnings, which is almost half Glaxo’s current price-to-earnings ratio of 15 times earnings. So AstraZeneca is either an opportunity, or a great big flashing warning signal. Which is it?

Five better options

Forecast earnings per share (EPS) growth of -19% this calendar year -5% in 2014 suggests the latter. Chief executive Pascal Soriot faces a battle to get this company back into gear, as governments across the West look to contain spiralling drugs budgets. His attempts could stall if AstraZeneca gets sucked into the Chinese bribery scandal, in the wake of GlaxoSmithKlein. The company denies any wrongdoing, but the Chinese authorities are sniffing menacingly. We’ll learn more about AstraZeneca’s prospects on Thursday, but for now, the only compelling reason to buy it is the yield. Mind you, 5.6% is quite compelling.

If you’re looking for a rock solid share to retire on, AstraZeneca isn’t it. You can discover far better stocks in our special report 5 Shares To Retire On. This free report by Motley Fool share analysts names five FTSE 100 favourites to secure your retirement. To find out more, download this report now. It won’t cost you a penny, so click here.

> Harvey owns shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »